USP7 and head and neck squamous cell carcinoma: Our findings reinforced that USP7 was a novel viable therapeutic target for HNSCC as genetic depletion or pharmacological inhibition of USP7 resulted in reduced tumor growth in vivo likely in part via TAZ inhibition.